Efficacy and response rates of the RENCA Macrobead therapy (RMB): A novel approach to the treatment of metastatic colorectal cancer. phase II clinical trials [US FDA BB-IND 10091]

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2020
This article has no abstract
Epistemonikos ID: 1053264bd4dda51fe0a2091dcb8b30c6eb569907
First added on: Feb 11, 2025